Laiv flumist
Phase 3
Laiv flumist is one of 37 therapeutic programs targeting Influenza. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
95 competitors in Influenza
#DrugCompanyPhaseTrials
1Influenza Vaccine
NovartisPhase 3
FLU Vaccine
GSKPhase 3
Inactivated Influenza Vaccine
SanofiPhase 3
Seasonal Influenza Vaccine
NovartisPhase 3
Live Attenuated Zoster Vaccine
CChangchun BCHT Biotechnology Co.
Phase 3
COVID-19 Vaccine
ModernaPhase 2
Relenza
GGlaxo Dba Glaxosmithkline
Phase 3
VAXIGRIP
GSKPhase 3
Dexametasone
UUniversity of Malaya
Phase 3
Baloxavir
IInsight Therapeutics, LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Laiv flumist. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- MMcMaster University